News Story #19223
AusAm Biotechnologies Receives Approval to Market Test for Kidney Disease AusAm Biotechnologies Inc has received the CE Mark of approval for the Microalbumin Plus™, which aids in the detection of microalbuminari
Read MorePosted by Clinical Lab Products | Dec 11, 2003 | Miscellaneous, Osteoporosis |
AusAm Biotechnologies Receives Approval to Market Test for Kidney Disease AusAm Biotechnologies Inc has received the CE Mark of approval for the Microalbumin Plus™, which aids in the detection of microalbuminari
Read MorePosted by Clinical Lab Products | Dec 6, 2003 | Cancer, Miscellaneous, Osteoporosis |
ImmuKnow™: A Pharmacodynamic Assay for Managing Immunosuppressive Drug Therapy
Read MorePosted by Clinical Lab Products | Dec 4, 2003 | Miscellaneous |
By Nicholas Borgert Bio-Rad Laboratories has expanded its TOX/See Rapid Urine Drug Screen platform with new capabilities to detect tricyclic antidepressants (TCA) and Ecstasy (MDMA). The new tests have been added to a TOX/See test menu tha
Read MorePosted by Clinical Lab Products | Sep 9, 2003 | Cancer, Miscellaneous |
Beckman Coulter Signs Agreement With Bio-Rad Beckman Coulter Inc has signed an agreement with Bio-Rad Laboratories Inc for the development, manufacture, and distribution of infectious disease and blood virus assays. The agreement will enable Beckm
Read MorePosted by Clinical Lab Products | Jul 9, 2003 | Cancer, Miscellaneous |
Roche launches pharmacogenomic microarray
Read More